Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States

IF 1 4区医学 Q4 ONCOLOGY

Bladder Cancer Pub Date : 2023-12-06 DOI:10.3233/blc-230062

Isabella R. Pompa, David Qi, Anushka Ghosh, Saveli I. Goldberg, Fumiko Chino, Jason A. Efstathiou, Sophia C. Kamran

{"title":"Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States","authors":"Isabella R. Pompa, David Qi, Anushka Ghosh, Saveli I. Goldberg, Fumiko Chino, Jason A. Efstathiou, Sophia C. Kamran","doi":"10.3233/blc-230062","DOIUrl":null,"url":null,"abstract":"<h4><span>Abstract</span></h4><h3><span></span>BACKGROUND:</h3><p>Bladder cancer is the tenth leading cause of cancer death in the United States (US). Advances in diagnosis, imaging, and treatments have led to improvements in bladder cancer management.</p><h3><span></span>OBJECTIVE:</h3><p>To evaluate longitudinal bladder cancer mortality trends from 1999–2020 in the US by gender, race, ethnicity, age, geographic region, and urbanization category.</p><h3><span></span>METHODS:</h3><p>Age-adjusted bladder cancer death and incidence rates of individuals in the US of all ages between 1999–2020 were obtained using the CDC WONDER and NAACCR databases. Trends and average annual percent changes (AAPC) in age-adjusted Bladder Cancer-Specific Mortality (BCSM) and incidence rates were estimated. Data were analyzed from May 2023 to October 2023.</p><h3><span></span>RESULTS:</h3><p>From 1999–2020, overall BCSM decreased by 0.4% annually, with a dramatic decrease in deaths between 2015–2020 (AAPC: –2.0% [95% CI: –2.6,–1.3]). However, BCSM rates and metastatic malignant bladder cancer incidence rates from 1999–2020 increased for individuals≥85 years old (AAPC for BCSM: 0.8% [95% CI:0.5,1.1]; AAPC for metastatic malignant incidence: 2.5% [95% CI: 2.0,2.9]). Increases in BCSM were found for certain years in the South, in rural areas, and for Non-Hispanic White and Asian or Pacific Islander individuals.</p><h3><span></span>CONCLUSIONS:</h3><p>Overall mortality from bladder cancer has been decreasing in the US over two decades. Upon disaggregation, increasing trends were found for BCSM and for metastatic malignant bladder cancer incidence for individuals≥85 years old from 1999–2020. Further evaluation of these trends is essential to understand how to target specific populations to improve patient outcomes.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"73 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/blc-230062","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND:

Bladder cancer is the tenth leading cause of cancer death in the United States (US). Advances in diagnosis, imaging, and treatments have led to improvements in bladder cancer management.

OBJECTIVE:

To evaluate longitudinal bladder cancer mortality trends from 1999–2020 in the US by gender, race, ethnicity, age, geographic region, and urbanization category.

METHODS:

Age-adjusted bladder cancer death and incidence rates of individuals in the US of all ages between 1999–2020 were obtained using the CDC WONDER and NAACCR databases. Trends and average annual percent changes (AAPC) in age-adjusted Bladder Cancer-Specific Mortality (BCSM) and incidence rates were estimated. Data were analyzed from May 2023 to October 2023.

RESULTS:

From 1999–2020, overall BCSM decreased by 0.4% annually, with a dramatic decrease in deaths between 2015–2020 (AAPC: –2.0% [95% CI: –2.6,–1.3]). However, BCSM rates and metastatic malignant bladder cancer incidence rates from 1999–2020 increased for individuals≥85 years old (AAPC for BCSM: 0.8% [95% CI:0.5,1.1]; AAPC for metastatic malignant incidence: 2.5% [95% CI: 2.0,2.9]). Increases in BCSM were found for certain years in the South, in rural areas, and for Non-Hispanic White and Asian or Pacific Islander individuals.

CONCLUSIONS:

Overall mortality from bladder cancer has been decreasing in the US over two decades. Upon disaggregation, increasing trends were found for BCSM and for metastatic malignant bladder cancer incidence for individuals≥85 years old from 1999–2020. Further evaluation of these trends is essential to understand how to target specific populations to improve patient outcomes.

查看原文本刊更多论文

美国膀胱癌死亡率趋势纵向分析

摘要背景：膀胱癌是美国第十大癌症死因。目的：根据性别、种族、民族、年龄、地理区域和城市化类别，评估 1999-2020 年美国膀胱癌死亡率的纵向趋势。方法：使用 CDC WONDER 和 NAACCR 数据库获取 1999-2020 年美国各年龄段的年龄调整后膀胱癌死亡率和发病率。估算了年龄调整后膀胱癌特异性死亡率（BCSM）和发病率的趋势和年均百分比变化（AAPC）。结果：1999-2020年间，膀胱癌总体死亡率（BCSM）每年下降0.4%，2015-2020年间死亡人数急剧下降（AAPC：-2.0% [95% CI：-2.6,-1.3]）。然而，1999-2020 年间，≥85 岁人群的 BCSM 率和转移性恶性膀胱癌发病率均有所上升（AAPC 的 BCSM 率：0.8% [95% CI：0.5,1.1]；AAPC 的转移性恶性发病率：2.5% [95% CI：2.0,2.9]）。结论：二十年来，美国膀胱癌的总死亡率一直在下降。细分后发现，1999-2020年间，膀胱癌死亡率和年龄≥85岁的转移性恶性膀胱癌发病率呈上升趋势。进一步评估这些趋势对于了解如何针对特定人群改善患者预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bladder Cancer Medicine-Urology

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.